Target intelligence / Profile preview

Bacterial FimH adhesin (FimH)

Target
FimH
Molecular classification
Bacterial adhesin, Lectin, Cell adhesion protein, Outer membrane protein, Non-enzymatic protein
01

Overview

The bacterial FimH adhesin is a two-domain, mannose-specific lectin located at the tip of type 1 fimbriae (pili) of Gram-negative enterobacteria, especially *Escherichia coli*. The N-terminal lectin domain mediates high-affinity binding to terminal mannose residues on host cell surface glycoproteins, facilitating bacterial adherence to epithelial cells and colonization, especially in the urinary tract. The C-terminal pilin domain anchors FimH to the fimbrial organelle and modulates its allosteric state and adhesive properties. FimH is essential to the pathogenesis of urinary tract and other infections by enabling bacteria to resist mechanical washout and establish persistent infections. Its adhesion employs a catch-bond mechanism, where ligand affinity increases under shear force, enabling robust host attachment during urine flow. This functional significance makes FimH a prominent antibacterial drug and vaccine target: small molecule mannosides and monoclonal antibodies have been designed to block its function. Numerous FimH structural variants exist among different bacterial strains, impacting tissue tropism and virulence.

Other names
FimHType 1 fimbrial adhesinType 1 pilus adhesinMannose-specific adhesin
02

Mechanism of action

Inhibition of mannose-binding to block bacterial adhesion; Competitive inhibition at carbohydrate-binding site; Antibody-mediated conformational trapping; Allosteric inhibition to prevent catch-bond formation

03

Biological functions

Bacterial adhesionHost–pathogen interactionCell attachmentBiofilm formationAllosteric signalingCatch-bond formation
04

Disease associations

InfectionUrinary tract infectionPathogenesis of uropathogenic Escherichia coli (UPEC)Bacterial colonizationBiofilm-associated diseases
05

Safety considerations

Potential for bacterial resistance via mutationTargeting may affect normal microbiota adhesionImmune-mediated cross-reactivity concernsSpecificity of inhibitors for pathogenic vs. commensal strains
06

Interacting drugs

Mannoside-based small molecule inhibitors

2 more in the full profile.

07

Biomarkers

FimH as a marker for type 1-piliated E. coli in urine/biofilmsAntibody response to FimH as a marker for vaccine efficacy

Beyond the preview

Go deeper on Bacterial FimH adhesin (FimH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bacterial FimH adhesin (FimH).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call